Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
On January 31, 2019, an 11-year old boy in Japan went to a medical clinic with a fever. The providers there diagnosed him with influenza, a strain called H3N2, and sent him home with a new medication called baloxavir.
Researchers have discovered a mutation in strains of influenza treated with a drug that makes the virus resistant to treatment.
There's no telling where the call will come from, or when. But Randy Cron, M.D., Ph.D., professor of pediatrics and medicine at UAB, knows to expect them.
A nationwide team of researchers has found an antibody that protects mice against a wide range of potentially lethal influenza viruses, advancing efforts to design of a universal vaccine that could either treat or protect people against all strains of the virus.
Researchers have found an antibody that protects mice against a wide range of lethal influenza viruses, according to a study from Washington University School of Medicine in St. Louis, Icahn School of Medicine at Mount Sinai in New York City, and Scripps Research in La Jolla, Calif.
A clinical trial in which healthy adults will be deliberately infected with influenza virus under carefully controlled conditions is recruiting volunteers at four Vaccine and Treatment Evaluation Units (VTEUs) supported by NIH's National Institute of Allergy and Infectious Diseases.
Researchers at the Icahn School of Medicine at Mount Sinai have received a contract award of up to $132 million from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), as part of a new Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to further develop the universal flu vaccine.
About 40 million people contracted the flu last year, with hundreds of thousands hospitalized and 35,400 to 61,000 deaths, including 134 children, according to the Centers for Disease Control and Prevention.
Every living person has trillions of microbes living in their digestive tract, and more than 400 species of bacteria in the gut, more than the number of cells in the body. The normal gut flora is important to maintain eubiosis, the microbial balance in the body.
The normal human gut microbiome is a flourishing community of microorganisms, some of which can affect the human immune system. In a new paper published this week in Cell, researchers found that oral antibiotics, which can kill gut microorganisms, can alter the human immune response to seasonal influenza vaccination.
For researchers with The Ohio State University College of Veterinary Medicine, the work to identify new flu strains and increase the effectiveness of the flu vaccine begins in an unlikely place – pig barns at state and county fairs nationwide.
Women tend to have a greater immune response to a flu vaccination compared to men, but their advantage largely disappears as they age and their estrogen levels decline, suggests a study from researchers at the Johns Hopkins Bloomberg School of Public Health.
In the race to create a universal flu vaccine not dependent on predicting strains of flu, the Virginia-Maryland College of Veterinary Medicine's Department of Veterinary Medicine at the University of Maryland College of Agriculture and Natural Resources has been awarded a $3.1 million grant.
New research could bring scientists a step closer to developing an effective, universal flu vaccine.
A study of influenza virus transmission in Nicaraguan households reveals new insights into the type of immune responses that may be protective against influenza virus infection, report investigators.
The ever-changing "head" of an influenza virus protein has an unexpected Achilles heel, report scientists funded by the National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health.
In a new series of articles, experts in immunology, virology, epidemiology, and vaccine development detail efforts to improve seasonal influenza vaccines and ultimately develop a universal influenza vaccine.
Michigan State University scientists have linked a common food preservative to an altered immune response that possibly hinders flu vaccines.
Most people who weather an infection with influenza fully recover after a week or two. But for some, a severe case of the flu can actually reshape the architecture of their lungs and forever compromise their respiratory function.
Results from a 10-year study suggest two strains of influenza that could mix and form a dangerous new strain of influenza spread by dogs.